EGFR and lung adenocarcinoma: The evidence in the previous literature regarding the optimal treatment strategy for the initial management of Asia patients with metastatic EGFR-mutant lung adenocarcinoma was questionable [5, 6, 17], although there are limited randomized trials directing this therapy.